Tandem Diabetes Care announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.
The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis.
"Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes," said John Sheridan, president and chief executive officer. "We are excited to continue our partnership with Abbott and look forward to working with them to bring this new integration to customers in the future."
